Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 47

Sort by

Sort Order Select

Journal Articles

Characteristics and Financial Impact of Potentially Inappropriate Platelet Transfusion in the Inpatient Hospital Setting

Eric Mou, MD, Colin Murphy, MD, Jason Hom, MD, Lisa Shieh, MD, Neil Shah, MD

Blood (2019) 134 (Supplement_1): 2096.

https://doi.org/10.1182/blood-2019-125949

Published: 2019

Journal Articles

Combined Targeting of Bcl-2 and XPO1 Overcomes Acquired Resistance to Tyrosine Kinase Inhibitors in the FLT3-ITD/TKD Double Mutant AML

Yoko Tabe, MD PhD, Kotoko Yamatani, MD, Haeun Yang, Kaori Saito, Yuko Murakami-Tonami, MD, Koya Suzuki, PhD, Weiguo Zhang, MD PhD, Sonoko Kinjo, PhD, Kazuho Ikeo, PhD, Masaki Hosoya, PhD, Kaoru Mogushi, PhD, Shigeo Yamaguchi, Hironori Harada, MD PhD, Takashi Miida, MD PhD, Neil Shah, MD, Marina Y. Konopleva, MD PhD, Yoshihide Hayashizaki, MD PhD, Michael Andreeff, MD PhD

Blood (2018) 132 (Supplement 1): 2640.

https://doi.org/10.1182/blood-2018-99-113195

Published: 2018

Journal Articles

Molecular Epidemiologic Associations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) within the United States

Adam Zrinski Albitar, BS, Neil Shah, MD, James K McCloskey, MD, Jamie L. Koprivnikar, MD, Jianhua Zhao, PhD, Chirag Desai, MS, MBA, Sucha Sudarsanam, MS, Maher Albitar, MD, Catherine E. Lai, MD

Blood (2018) 132 (Supplement 1): 1393.

https://doi.org/10.1182/blood-2018-99-117365

Published: 2018

Journal Articles

Using Electronic Best Practice Alerts to Improve Thrombophilia Testing Based on ASH Choosing Wisely Guidelines

Tomi Jun, MD, Henry Kwang, MD, Eric Mou, MD, Caroline Berube, MD, Neil Shah, MD, Rajani Kaimal, MS, Jason Bentley, PhD, Neera Ahuja, MD, Lisa Shieh, MD, Jason Hom, MD

Blood (2017) 130 (Supplement 1): 3355.

https://doi.org/10.1182/blood.V130.Suppl_1.3355.3355

Published: 2017

Journal Articles

Successful Renal Transplant Tolerance Following a Haplo-Identical Allogenic Hematopoietic Stem Cell Transplant - a Case Report and Review of Literature

Neil Shah, MD, Adam S. Vesole, BBA, Michele L. Donato, MD, David S. Siegel, MD PhD, Joshua R. Richter, MD, Noa Biran, MD, Alan P Skarbnik, MD, Robert Korngold, PhD, Scott D. Rowley, MD, David H. Vesole, MD PhD

Blood (2016) 128 (22): 5879.

https://doi.org/10.1182/blood.V128.22.5879.5879

Published: 2016

Journal Articles

Prevalence and Financial Impact of Inappropriate Thrombophilia Testing in the Inpatient Hospital Setting: A Retrospective Analysis

Eric Mou, MD, Henry Kwang, MD, Jason Hom, MD, Lisa Shieh, MD, Neera Ahuja, MD, Stephanie Harman, MD, Tyler Johnson, MD, Andre Kumar, MD, Neil Shah, MD, Ronald Witteles, MD, Caroline Berube, MD FRCP(C)

Blood (2016) 128 (22): 2330.

https://doi.org/10.1182/blood.V128.22.2330.2330

Published: 2016

Journal Articles

Long-Term Follow-up of the Efficacy and Safety of Ponatinib in Philadelphia Chromosome-Positive Leukemia Patients with the T315I Mutation

Elias J. Jabbour, MD, Jorge E. Cortes, MD, Moshe Talpaz, MD, Michele Baccarani, MD, Michael J. Mauro, MD, Andreas Hochhaus, MD, Timothy P. Hughes, MD FRACP, FRCPA, MBBS, FAAHMS, Francois Guilhot, MD, Michael W. Deininger, MD PhD, Neil Shah, MD PhD, Dale L. Bixby, MD, Ian W. Flinn, MD PhD, Thomas O'Hare, PhD, Stephanie Lustgarten, PhD, Victor M. Rivera, PhD, Sergio Santillana, MD, Hagop M. Kantarjian, MD

Blood (2016) 128 (22): 3067.

https://doi.org/10.1182/blood.V128.22.3067.3067

Published: 2016

Journal Articles

Stem cell transplantation for tetratricopeptide repeat domain 7A deficiency: long-term follow-up

Jochen Kammermeier, Giovanna Lucchini, Sung-Yun Pai, Austen Worth, Dyanne Rampling, Persis Amrolia, Juliana Silva, Robert Chiesa, Kanchan Rao, Gabriele Noble-Jamieson, Marco Gasparetto, Drew Ellershaw, Holm Uhlig, Neil Sebire, Mamoun Elawad, Luigi Notarangelo, Neil Shah, Paul Veys

Blood (2016) 128 (9): 1306–1308.

https://doi.org/10.1182/blood-2016-01-696385

Published: 2016

Includes: Supplemental data

Journal Articles

Outcomes of Salvage Stem Cell Transplantation in Hodgkin Lymphoma in a Single Institution in the Modern Era

Tatyana Feldman, MD, Larysa Sanchez, MD, Lina Starovoitova, BS, Ewelina Protomastro, MS, Yucai Wang, MD PhD, Neil Shah, MD, Michele L. Donato, MD, Scott D. Rowley, MD FACP, David H. Vesole, MD, Alan P Skarbnik, MD, Andrew L. Pecora, MD, Andre Goy, MD MS

Blood (2015) 126 (23): 5500.

https://doi.org/10.1182/blood.V126.23.5500.5500

Published: 2015

Journal Articles

High Rate of Engraftment Syndrome in Elderly Patients with Multiple Myeloma Receiving Autologous Peripheral Blood Stem Cell Transplantation

Phyllis McKiernan, APN, MSN, OCN, David Siegel, MD PhD, David H. Vesole, MD, Themba Nyirenda, PhD, Scott D. Rowley, MD FACP, Alan P Skarbnik, MD, Ann Ferolin-Ocot, RN, BSN, OCN, Daniel Kim, Neil Shah, MD, Michele L. Donato, MD

Blood (2015) 126 (23): 3175.

https://doi.org/10.1182/blood.V126.23.3175.3175

Published: 2015

Journal Articles

Improved Hospital-Wide RBC Utilization Via Clinical Decision Support Is Associated With Stable Or Improving Patient Outcomes

Lawrence T Goodnough, M.D., Neil Shah, M.D., Eric Hadhazy, Lisa Shieh, MD, PhD, Paul Maggio, M.D.

Blood (2013) 122 (21): 1152.

https://doi.org/10.1182/blood.V122.21.1152.1152

Published: 2013

Journal Articles

Crenolanib (CP-868,596) Is a Potent and Selective Type I FLT3 Inhibitor That Retains Activity Against AC220 Resistance-Causing FLT3 Kinase Domain Mutants

Catherine C Smith, MD, Elisabeth Lasater, PhD, Melissa Mccreery, BS, Kimberly Lin, BS, Whitney Stewart, BS, Lauren E Damon, Alexander E Perl, MD, Grace R Jeschke, Mayumi Sugita, MD, Martin Carroll, MD, Scott C. Kogan, MD, Neil Shah, MD, PhD

Blood (2012) 120 (21): 141.

https://doi.org/10.1182/blood.V120.21.141.141

Published: 2012

Journal Articles

Early Response (Molecular and Cytogenetic) and Long-Term Outcomes in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Analysis of DASISION 3-Year Data

Giuseppe Saglio, MD, Hagop M. Kantarjian, MD, Neil Shah, MD, PhD, Elias J. Jabbour, MD, Alfonso Quintas-Cardama, MD, Juan Luis Steegmann, MD, PhD, Concepción Boqué, MD, Charles Chuah, MD, Carolina Pavlovsky, MD, Jiří Mayer, MD, Jon Ukropec, PhD, Mark Wildgust, PhD, Andreas Hochhaus, MD

Blood (2012) 120 (21): 1675.

https://doi.org/10.1182/blood.V120.21.1675.1675

Published: 2012

Journal Articles

A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial

Blood (2012) 120 (21): 163.

https://doi.org/10.1182/blood.V120.21.163.163

Published: 2012

Journal Articles

Efficacy and Safety of Ponatinib According to Prior Approved Tyrosine Kinase Inhibitor (TKI) Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CP-CML): Results From the PACE Trial

Blood (2012) 120 (21): 3749.

https://doi.org/10.1182/blood.V120.21.3749.3749

Published: 2012

Journal Articles

Molecular Responses with Ponatinib in Patients with Philadelphia Chromosome Positive (Ph+) Leukemia: Results From the PACE Trial

Blood (2012) 120 (21): 3763.

https://doi.org/10.1182/blood.V120.21.3763.3763

Published: 2012

Journal Articles

Long-Term Anti-Leukemic Activity of Ponatinib in Patients with Philadelphia Chromosome-Positive Leukemia: Updated Results from an Ongoing Phase 1 Study

Michael W Deininger, MD, PhD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Neil Shah, MD, PhD, Dale Bixby, MD, PhD, Michael J. Mauro, MD, Ian W. Flinn, MD, PhD, Thomas O'Hare, PhD, Simin Hu, PhD, David J. Dorer, Victor M. Rivera, PhD, Tim Clackson, PhD, Christopher D. Turner, MD, FAAP, Frank G Haluska, MD, PhD, Brian J. Druker, Moshe Talpaz, MD

Blood (2012) 120 (21): 3743.

https://doi.org/10.1182/blood.V120.21.3743.3743

Published: 2012

Journal Articles

Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Treated with Ponatinib in the PACE Trial

Blood (2012) 120 (21): 3747.

https://doi.org/10.1182/blood.V120.21.3747.3747

Published: 2012

Journal Articles

Clinical Impact of an Internet-Based Tool to Help Guide Therapeutic Changes While Monitoring Patients with Chronic Myeloid Leukemia Receiving First-Line Tyrosine Kinase Inhibitor Therapy

Kevin L. Obholz, PhD, Daniel J. DeAngelo, MD, PhD, Michael J. Mauro, MD, Neil Shah, MD, PhD, B. Douglas Smith, MD, Andrew Bowser, ELS, CCMEP, Eric D. Peterson, EdM, FACEHP, Jerald P. Radich, MD

Blood (2012) 120 (21): 4279.

https://doi.org/10.1182/blood.V120.21.4279.4279

Published: 2012

Journal Articles

Competitive Allele Specific TaqMan® PCR (castPCR™) Technology for Sensitive Detection of AC220-Resistant FLT3 Kinase Domain Mutations in Primary AML Patient Samples.

Willard Cheng, BS, Elisabeth Lasater, PhD, Catherine C Smith, MD, Mouanoutoua Mokang, Yun Bao, PhD, Neil Shah, MD, PhD

Blood (2012) 120 (21): 2559.

https://doi.org/10.1182/blood.V120.21.2559.2559

Published: 2012

NARROW

Characteristics and Financial Impact of Potentially Inappropriate Platelet Transfusion in the Inpatient Hospital Setting

Combined Targeting of Bcl-2 and XPO1 Overcomes Acquired Resistance to Tyrosine Kinase Inhibitors in the FLT3-ITD/TKD Double Mutant AML

Molecular Epidemiologic Associations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) within the United States

Using Electronic Best Practice Alerts to Improve Thrombophilia Testing Based on ASH Choosing Wisely Guidelines

Successful Renal Transplant Tolerance Following a Haplo-Identical Allogenic Hematopoietic Stem Cell Transplant - a Case Report and Review of Literature

Prevalence and Financial Impact of Inappropriate Thrombophilia Testing in the Inpatient Hospital Setting: A Retrospective Analysis

Long-Term Follow-up of the Efficacy and Safety of Ponatinib in Philadelphia Chromosome-Positive Leukemia Patients with the T315I Mutation

Stem cell transplantation for tetratricopeptide repeat domain 7A deficiency: long-term follow-up

Outcomes of Salvage Stem Cell Transplantation in Hodgkin Lymphoma in a Single Institution in the Modern Era

High Rate of Engraftment Syndrome in Elderly Patients with Multiple Myeloma Receiving Autologous Peripheral Blood Stem Cell Transplantation

Improved Hospital-Wide RBC Utilization Via Clinical Decision Support Is Associated With Stable Or Improving Patient Outcomes

Crenolanib (CP-868,596) Is a Potent and Selective Type I FLT3 Inhibitor That Retains Activity Against AC220 Resistance-Causing FLT3 Kinase Domain Mutants

Early Response (Molecular and Cytogenetic) and Long-Term Outcomes in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Analysis of DASISION 3-Year Data

A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial

Efficacy and Safety of Ponatinib According to Prior Approved Tyrosine Kinase Inhibitor (TKI) Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CP-CML): Results From the PACE Trial

Molecular Responses with Ponatinib in Patients with Philadelphia Chromosome Positive (Ph+) Leukemia: Results From the PACE Trial

Long-Term Anti-Leukemic Activity of Ponatinib in Patients with Philadelphia Chromosome-Positive Leukemia: Updated Results from an Ongoing Phase 1 Study

Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Treated with Ponatinib in the PACE Trial

Clinical Impact of an Internet-Based Tool to Help Guide Therapeutic Changes While Monitoring Patients with Chronic Myeloid Leukemia Receiving First-Line Tyrosine Kinase Inhibitor Therapy

Competitive Allele Specific TaqMan® PCR (castPCR™) Technology for Sensitive Detection of AC220-Resistant FLT3 Kinase Domain Mutations in Primary AML Patient Samples.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only